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Abstract 
The synthesis and antimicrobial evaluation of new 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-
ylthio]acetohydrazide derivatives was investigated. According to the literature, there are a lot of 
antimicrobial agents among the pyrimidines and hydrazides, and therefore it seems promising to use 2-[6-
methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide as a base object for synthesizing new 
biologically active substances. 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide was 
obtained by the hydrazinolysis of ethyl thioacetate, using a 3-fold molar excess of 85 % hydrazine hydrate 
in ethanol, at room temperature. Interaction of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-
acetohydrazide with ketones during boiling in ethanol yielded N-ylidenehydrazides. The solid obtained by 





C NMR, IR spectroscopy and elemental analysis. The antibacterial and antifungal 
activities of the new compounds were analysed using agar diffusion and tenfold broth (pH 7.2 – 7.4) 
dilution methods, in comparison with the clinical used drugs, ceftriaxone and Pimafucin. The structure–
activity studies showed that, depending on the nature of the hydrazide fragment, the newly synthesized 
compounds exhibited varying degrees of microbial inhibition. Within the same series the antimicrobial 
activity depends on the nature of the substituent attached to the benzene ring. The investigation of 
antibacterial screening data revealed that the compounds Nʹ-[1-(4-aminophenyl)ethylidene]-2-[6-methyl-
4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, Nʹ-[1-(4-hydroxyphenyl)ethylidene]-2-[6-methyl-4-
(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, Nʹ-[1- (2,5-dihydroxyphenyl) ethylidene]-2-[6-methyl-
4-(thietan-3-yloxy)-pyrimidin-2-ylthio]acetohydrazide were found to be more potent than the other 
synthesized analogues.  
©2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
Infectious diseases are still a challenging global problem and a major public health threat, and this has 
led to the research and development of new antibiotics for multi-drug resistant microbial pathogens. 
Fungal and bacterial agents affect internal organs like the mucous membrane of the respiratory, 
gastrointestinal and urinary tracts, and cause different diseases [1,2]. Increasingly, there is a growing 
number of individuals with a weakened immune system who can get infected. 
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Over the last decade there has been considerable interest in the synthesis and pharmacological study of 
pyrimidine derivatives [3-7]. The pyrimidine fragment has been gaining special interest as it is part of many 
biological active compounds: vitamins, nucleotides and nucleosides. Our research group has published 
much research in the field of the synthesis of thietan derivatives [8,9] as they possess a broad spectrum of 
bioactivities: antimicrobial [10,11], hypotensive [12,13], broncholytic [14] and wound healing [15,16]. 
Compounds containing thietan and pyrimidine in their molecules are suitable candidates for further 
chemical modifications and may be pharmacologically active. We report the synthesis of new derivatives of 
2-thiopyrimidine containing thietan ring, and investigate their antibacterial and antifungal properties.  
Experimental  
Materials and methods 
The reagents used in the experiments were all commercially available without further purification. Each 
reaction was monitored by thin layer chromatography (TLC) on Sorbfil PTSX-AF-A-UV plates using ethyl 
acetate. Visualization on TLC was achieved by UV light or iodine indicator. 
Melting points were recorded on PTP-M (Russia) melting point apparatus uncorrected. Infrared spectra 
were recorded in KBr pellets on an Infralum FT-02 (Russia) spectrophotometer. 1H and 13C NMR spectra 
were recorded on Bruker AMX-300 300 MHz and Bruker Avance III 500 MHz in CDCl3 and DMSO-d6 using 
tetramethylsilane as internal standard (chemical shifts were expressed as δ-values, J in hertz). CHNS 
elemental analyses were performed on a Hekatech Euro-EA (Germany) elemental analyzer. 
Ethyl 2-[6-methyl-4-(tietan-3-yloxy)pyrimidine-2-ylthio]acetate (1) was synthesized by interaction of 
ethyl-2-(6-methyl-4-oxo-3,5-dihydropyrimidine-2-ilthio)acetate with 2-chloromethylthiirane [16] (Figure 1). 
Ethyl 2-[6-methyl-4-(tietan-3-yloxy)pyrimidine-2-ylthio]acetate (compound 1) 
Light yellow crystalline powder. Recrystallization from mixture EtOH-water (3:1). Yield: 42 %; m.p. 61 °C. 
IR (KBr) in cm−1: 1630 (νС=О), 3280 (νN-H), 1530 (δN-H); 1572-1591 (С=С, С=N), 2960 (νC-H), 1443 (δC=C6-
CH3), 1167, 1050 (C-O-C), 1750 (νCH2-COOR). 
1H NMR (300 MHz, CDCl3, δ, ppm): 1.31 t (3Н, СН3, Et, J 7.1 
Hz); 2.34 s (3H, 6-CH3); 3.38-3.48 m [2Н, S(CH)2]; 3.48-3.58 m [2Н, S(CH)2]; 3.82 s (2Н, SCH2CO); 4.22 q (2Н, 
ОCH2, Et, J 4,1 Hz); 5.55-5.57 m (1Н, OCH); 6.21 s (1H, 5-H). 
13C NMR (125.5 MHz, CDCl3, δ, ppm): 168.52 
(C6); 23.11 (6C-CH3); 101.91 (
5CH); 166.95 (4C); 69.63 (OC3); 34.50 (SC2,4); 169.17 (2C); 32.51 (2-SCH2CO); 
166.79 (2-SCH2CO), 60,61 (CH2CH3), 14,15 (CH2CH3). Found, %: C 47.96; H 5.39; N 9.43; S 21.35. 
C12H16N2O3S2. Calculated, %: C 47.98; H 5.37; N 9.33; S 21.35. 
(E,Z)-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide (compound 2) 
Light yellow crystalline powder. 85% hydrazine hydrate (0.29 g, 0.00501 mol) solution was added to a 
solution of compound 1 (0.5 g, 0.00167 mol) in 3 ml of ethanol. The reaction mixture was mixed at room 
temperature for 4 hours. The product which precipitated was filtered, dried and recrystallized from i-PrOH. 
Yield: 0.32 g (67%); m.p. 119-120°C. IR (KBr) in cm−1: 1630 (νС=О), 3280 (νN-H), 1520 (δN-H); 1572-1591 
(С=С, С=N), 2960 (νC-H), 1443 (δC=C6-CH3), 1167, 1050 (C-O-C). 
1H NMR (300 MHz, C6D6, δ, ppm): 2.30 (3Н, 
s, 6C–CH3,), 3.42-3.49, (4H, m, S(CH2)2), 5.76-5.82 (1H, m, OCH), 6,50 (Z), 6,48 (E) (1H, s, 
5C–H), 3,78 (Z), 4,18 
(E) s (2Н, SCH2СО); 4,30 (Z), 4,54 (E) wid. s (2Н, NН2); 8,61 (E), 9,31 (Z) wid. s (1Н, NH). 
13C NMR (125.5 MHz, 
CDCl3, δ, ppm): 168.52 (C
6); 23.11 (6C-CH3); 101.91 (
5CH); 166.95 (4C); 69.63 (OC3); 34.50 (SC2,4); 169.17 (2C); 
32.51 (2-SCH2CO); 166.79 (2-SCH2CO). Found,%: C 41.95; H 4.93; N 19.57; S 22.39. C10H14N4O2S2. 
Calculated,%: C 41.94; H 4.93; N 19.57; S 22.39. 
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Figure 1. Synthetic route of the synthesized compounds 1-12 
General procedure for the synthesis of compound 3-12 
Appropriate ketone was added to a solution of compound 2 in 5 ml of ethanol (Figure 1). The reaction 
mixture was boiled for 1 h. The solid obtained by concentration was collected and purified by 
recrystallization. 
(E,Z)-2-[6-Methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-Nʹ-(propan-2-ylidene)acetohydrazide (compound 3) 
White solid. Recrystallization from EtOH. Yield: 0.21 g (61%); m.p. 141-142 °C. IR (KBr) in cm−1: 1670 
(«amide I»), 1650 (C=O), 1588, 1572 (С=N, С=С), 1546 (δ NH, «amide II»), 1393 (δС-Н), 1164 (nas), 1045 (ns) 
(C-O-C). 1H NMR (300 MHz, C6D6, δ, ppm): 2.10 (3Н, s,
 6C–CH3,), 3.12-3.19, 3.31-3.37 (4H, m, S(CH2)2), 5.62-
5.63 (1H, m, OCH), 5.82 (1H, s, 5C–H), 4.44 (1H, s, SCH2CO), 9.94 (1H, wid s, CONH), 1.47 s (3Н, =С(СН3)); 
1.65 s (3Н, =С(СН3)). 
1H NMR (300 MHz, DMSO-d6, δ, ppm): 2.29 (E), 2.50 (Z) (3Н, s,
 6C–CH3,), 3.35-3.49 (Z, E) 
(4H, m, S(CH2)2), 5.68-5.77 (E, Z) (1H, m, OCH), 6.45 (E), 6.48 (Z) (1H, s, 
5C–H), 3.92 (Z), 4.26 (E) (1H, s, 
SCH2CO), 10.29 (Z), 10.39 (E) (1H, wid s, CONH), 1.90 (E), 1.91 (Z) s (3Н, =С(СН3)); 1.92 (Z), 1.94 (E) s (3Н, 
=С(СН3)). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.35 (Z), 2.41 (E) (3Н, s,
 6C–CH3,), 3.33-3.37, 3.41-3.45(E), 3.49-
3.54 (Z) (4H, m, S(CH2)2), 5.78-5.86 (E, Z) (1H, m, OCH), 6.19 (E), 6.30 (Z) (1H, s, 
5C–H), 3.87 (Z), 4.29 (E) (1H, 
s, SCH2CO), 8.56 (Z), 9.57 (E) (1H, wid s, CONH), 1.78 (E), 1.91 (Z) s (3Н, =С(СН3)); 2.05 (Z), 2.07 (E) s (3Н, 
=С(СН3)). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 165.07 (E, Z) (C
6); 25.41 (E); 25.48 (Z) (6C-CH3); 102.13 (Z); 
103.30 (E) (5CH); 167.45 (Z); 167.65(E) (4C); 69.51 (Z); 70.29 (E) (OC3); 35.10 (E); 35.56 (Z) (SC2,4); 168.30 (E); 
168.49 (Z) (2C); 33.35 (Z); 33.58 (E) (2-SCH2CO); 169.44 (Z); 170.02 (E) (2-SCH2CO); 16.10 (Z), 16.91 (E) 
(N=C(CH3)); 23.72 (Z), 23.93 (E) (N=C(CH3)); 150.21 (Z), 155.49 (E) (N=C). Found,%: C 47.83; H 5.56; N, 17.16; 
S 19.64. C13H18N4O2S2. Calculated,%: C 47.83; H 5.56; N, 17.16; S 19.64.  
(E,Z)-Nʹ-(Butan-2-ylidene)-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-yl-thio]acetohydrazide (compound 4) 
White solid. Recrystallization from EtOH. Yield: 0.29 g (81%); m.p. 131-132 °C. IR (KBr) in cm−1: 1675 
(«amide I»), 1645 (C=O), 1586, 1571 (С=N, С=С), 1546 (δ NH, «amide II»), 1393 (δС-Н), 1168 (nas), 1050 (ns) 
(C-O-C). 1H NMR (300 MHz, CDCl3, δ, ppm): 2.07 (Z), 2.12 (E) (3Н, s,
 6C–CH3,), 3.42-3.45(E), 3.49-3.53 (Z) (4H, 
m, S(CH2)2), 5.73-5.86 (E, Z) (1H, m, OCH), 5.95 (E), 6.11 (Z) (1H, s, 
5C–H), 4.01 (Z), 4.29 (E) (1H, s, SCH2CO), 
9.57 (Z), 10.57 (E) (1H, wid s, CONH), 2.05 (E), 2.17 (Z) m (2Н, =ССН2); 1.92 (Z), 1.99 (E) s (3Н, =ССН3), 0.83 
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(Z), 1.08 (E) t (3Н, =ССН2CH3). 
13C NMR (125.5 MHz, CDCl3, δ, ppm): 166.02 (E, Z) (C
6); 23.74 (E); 23.88 (Z) 
(6C-CH3); 101.43 (Z); 102.30 (E) (
5CH); 168.45 (Z); 168.65(E) (4C); 67.41 (Z); 68.39 (E) (OC3); 34.10 (E); 34.76 
(Z) (SC2,4); 169.40 (E); 169.48 (Z) (2C); 35.36 (Z); 35.78 (E) (2-SCH2CO); 170.42 (Z); 171.01 (E) (2-SCH2CO); 
13.20 (Z), 13.81 (E) (N=C(CH3)); 11.12 (Z), 12.11 (E) (CH3); 26.22 (Z), 26.92 (E) (N=C(CH2)); 158.11 (Z), 158.39 
(E) (N=C). Found,%: C 49.39; H 5.92; N, 16.46; S 18.83. C14H20N4O2S2. Calculated,%: C 49.39; H 5.92; N, 16.46; 
S 18.83. 
(E,Z)-Nʹ-(Cyclohexylidene)-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-yl-thio]acetohydrazide (compound 5) 
White solid. Recrystallization from n-BuOH. Yield: 0.34 g (89%); m.p. 180-181 °C. IR (KBr) in cm−1: 1661 
(«amide I»), 1580, 1566 (С=N, С=С), 1546 (δ NH, «amide II»), 1449-1432 (n CH2 cyclohexane), 1164 (nas), 1047 
(ns) (C-O-C), 768 (C-S). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.06 (Z), 2.12 (E) (3Н, s,
 6C–CH3,), 3.41-3.48(E), 
3.37-3.45 (Z) (4H, m, S(CH2)2), 5.73-5.86 (E, Z) (1H, m, OCH), 5.95 (E), 6.11 (Z) (1H, s, 
5C–H), 4.11 (Z), 4.21 (E) 
(1H, s, SCH2CO), 9.56 (Z), 10.51 (E) (1H, wid s, CONH), 2.34 t (4Н, =С(СН2)2); 1.65 t (6Н, (СН2)3). 
13C NMR 
(125.5 MHz, CDCl3, δ, ppm): 166.14 (E, Z) (C
6); 23.84 (E); 23.98 (Z) (6C-CH3); 101.23 (Z); 102.36 (E) (
5CH); 
168.25 (Z); 168.85(E) (4C); 66.34 (Z); 67.58 (E) (OC3); 34.12 (E); 34.78 (Z) (SC2,4); 169.30 (E); 169.58 (Z) (2C); 
39.26 (Z); 40.71 (E) (2-SCH2CO); 171.12 (Z); 172.02 (E) (2-SCH2CO); 28.14 (E, Z) (N=C(CH2); 34.12 (E, Z) 
(N=C(CH2); 27.58 (E, Z) (2CH2); 25.8 (E, Z) (CH2); 167.21 (Z), 167.39 (E) (N=C). Found,%: C 52.44; H, 6.06; N, 
15.29; S 17.51. C16H22N4O2S2. Calculated,%: C 52.44; H 6.05; N, 15.29; S 17.50. 
(E,Z)-Nʹ-[1-(4-Aminophenyl)ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide 
(compound 6) 
Pale yellow solid. Recrystallization from n-BuOH. Yield: 0.35 g (83%); m.p. 176-177 °C. . IR (KBr) in cm−1: 
3470 (NH2), 3187-3299 (CHarom), 1667 («amide I»), 1588, 1574 (С=N, С=С), 1549 (δ NH, «amide II»), 1164 
(nas), 1045 (ns) (C-O-C), 799 (C-S). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.08 (Z), 2.23 (E) (3Н, s,
 6C–CH3,), 3.28-
3.34(E), 3.44-3.50 (Z) (4H, m, S(CH2)2), 5.79-5.90 (E, Z) (1H, m, OCH), 6.18 (E), 6.30 (Z) (1H, s, 
5C–H), 3.87 (Z), 
3.92 (E) (1H, s, SCH2CO), 8.69 (Z), 9.72 (E) (1H, wid s, CONH), 2.34 (E), 2.43 (Z) s (3H, N=C(CH3)); 6.18 (E, Z) s 
(2H, NH2); 6.67 (E, Z) d (2Нarom, J 8.4 Hz); 7.60 (E, Z) d (2Нarom, J 8.6 Hz). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 
165.97 (E, Z) (C6); 23.61 (E); 24.08 (Z) (6C-CH3); 102.29 (E); 103.54 (Z) (
5CH); 167.46 (E, Z); (4C); 69.47 (E); 
70.23 (Z) (OC3); 35.09 (Z); 35.49 (E) (SC2,4); 168.49 (E, Z) (2C); 33.36 (E); 33.80 (Z) (2-SCH2CO); 170.78 (E, Z) (2-
SCH2CO); 12.95 (E), 13.69 (Z) (=C(CH3)); 126.15 (E), 126.63 (Z) (2СНarom); 129.51 (E), 129.69 (Z) (2СНarom); 
137.45 (E, Z) (Сarom); 148.29 (E), 149.05 (Z) (=C(CH3)). Found,%: C 53.58; H 5.25; N, 17.36; S 15.89. 
C18H21N5O2S2. Calculated,%: C 53.58; H 5.25; N, 17.36; S 15.89. 
(E,Z)-2-[6-Methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-Nʹ-(1-phenylethylidene)acetohydrazide (compound 
7) 
White solid. Recrystallization from n-BuOH. Yield: 0.32 g (79%); m.p. 178-179 °C. IR (KBr) in cm−1: 3187-
3299 (CHarom), 1667 («amide I»), 1588, 1574 (С=N, С=С), 1549 (δ NH, «amide II»), 1164 (nas), 1045 (ns) (C-O-
C), 799 (C-S). 1H NMR (300 MHz, CDCl3, δ, ppm): 2.14 (Z), 2.30 (E) (3Н, s,
 6C–CH3,), 3.28-3.31(E), 3.42-3.53 (Z) 
(4H, m, S(CH2)2), 5.77-5.87 (E, Z) (1H, m, OCH), 6.17 (E), 6.31 (Z) (1H, s, 
5C–H), 3.93 (Z), 4.42 (E) (1H, s, 
SCH2CO), 9.14 (E), 9.87 (Z) (1H, wid s, CONH), 2.33 (E), 2.44 (Z) s (3H, N=C(CH3)); 7.38-7.42 (E, Z) m (3Нarom); 
7.74-7.79 (E, Z) м (2Нarom). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 165.98 (E, Z) (C
6); 23.71 (E); 24.01 (Z) (6C-
CH3); 102.19 (E); 103.34 (Z) (
5CH); 167.46 (E, Z); (4C); 69.47 (E); 70.23 (Z) (OC3); 35.09 (Z); 35.49 (E) (SC2,4); 
168.49 (E, Z) (2C); 33.36 (E); 33.80 (Z) (2-SCH2CO); 170.78 (E, Z) (2-SCH2CO); 12,95 (E), 13,69 (Z) (=C(CH3)); 
126,15 (E), 126,63 (Z) (СНarom); 128,33 (Z), 128,47 (E) (СНarom); 129,51 (E), 129,69 (Z) (СНarom); 137,65 (E, Z) 
(Сarom); 148,29 (E), 149,05 (Z) (=C(CH3)). Found,%: C 55.61; H 5.19; N, 14.42; S 16.50. C18H20N4O2S2. 
Calculated,%: C 55.65; H 5.19; N, 14.42; S 16.50. 
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(E,Z)-Nʹ-[1-(4-Chlorophenyl)ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide 
(compound 8) 
White solid. Recrystallization from i-BuOH. Yield: 0.32 g (79%); m.p. 170-171 °C. IR (KBr) in cm−1: 1630 
(nС=О), 3280 (nN-H), 1520 (dN-H); 1572-1591 (С=С, С=N), 2960 (nC-H), 1443 (dC=C6-CH3), 1167, 1050 (C-O-
C), 1090 (C-Cl). 1H NMR (300 MHz, CDCl3, δ, ppm): 2.12 (Z), 2.18 (E) (3Н, s,
 6C–CH3,), 3.26-3.31(E), 3.41-3.54 
(Z) (4H, m, S(CH2)2), 5.77-5.85 (E, Z) (1H, m, OCH), 6.19 (E), 6.31 (Z) (1H, s, 
5C–H), 3.93 (Z), 4.40 (E) (1H, s, 
SCH2CO), 9.02 (E), 9.90 (Z) (1H, wid s, CONH), 2.33 (E), 2.44 (Z) s (3H, N=C(CH3)); 7.37 (E, Z) d (2Нarom, J 8.4 
Hz); 7.71 (E, Z) d (2Нarom, J 7.5 Hz). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 163.78 (E, Z) (C
6); 23.71 (E); 23.97 
(Z) (6C-CH3); 102.22 (E); 103.37 (Z) (
5CH); 167.45 (E, Z); (4C); 69.43 (E); 70.22 (Z) (OC3); 35.09 (Z); 35.49 (E) 
(SC2,4); 168.52 (E, Z) (2C); 33.30 (E); 33.78 (Z) (2-SCH2CO); 170.90 (E, Z) (2-SCH2CO); 12,87 (E), 13,48 (Z) 
(=C(CH3)); 123,87 (E, Z) (2СНarom); 131,49 (Z), 131,74 (E) (2СНarom); 136,86 (E, Z) (2Сarom); 147,57 (E, Z) 
(=C(CH3)). Found,%: C 51.12; H 4.53; N 13.25; S 15.16. C18H19ClN4O2S2. Calculated,%: C 51.12; H 4.53; N 
13.25; S 15.16. 
(E,Z)-Nʹ-[1-(4-Bromophenyl)ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide 
(compound 9) 
White solid. Recrystallization from n-BuOH. Yield: 0.40 g (81%); m.p. 178-179 °C. IR (KBr) in cm−1: 1630 
(nС=О), 3280 (nN-H), 1520 (dN-H); 1572-1591 (С=С, С=N), 2960 (nC-H), 1443 (dC=C6-CH3), 1167, 1050 (C-O-
C), 1050 (C-Br). 1H NMR (300 MHz, CDCl3, δ, ppm): 2.11 (Z), 2.28 (E) (3Н, s,
 6C–CH3,), 3.26-3.30(E), 3.41-3.52 
(Z) (4H, m, S(CH2)2), 5.75-5.87 (E, Z) (1H, m, OCH), 6.17 (E), 6.31 (Z) (1H, s, 
5C–H), 3.92 (Z), 4.39 (E) (1H, s, 
SCH2CO), 9.30 (E), 9.91 (Z) (1H, wid s, CONH), 2.32 (E), 2.43 (Z) s (3H, N=C(CH3)); 6.91 (E, Z) d (2Нarom, J 8,7 
Hz), 7.51 (E, Z) d (2Нarom, J 8,6 Hz). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 163.78 (E, Z) (C
6); 23.71 (E); 23.97 
(Z) (6C-CH3); 102.22 (E); 103.37 (Z) (
5CH); 167.45 (E, Z); (4C); 69.43 (E); 70.22 (Z) (OC3); 35.09 (Z); 35.49 (E) 
(SC2,4); 168.52 (E, Z) (2C); 33.30 (E); 33.78 (Z) (2-SCH2CO); 170.90 (E, Z) (2-SCH2CO); 12,87 (E), 13,48 (Z) 
(=C(CH3)); 123,87 (E, Z) (2СНarom); 131,49 (Z), 131,64 (E) (2СНarom); 136,56 (E, Z) (2Сarom); 147,30 (E, Z) 
(=C(CH3)). Found,%: C 46.26; H 4.10; N, 11.93; S 13.72. C18H19BrN4O2S2. Calculated,%: C 46.26; H 4.10; N, 
11.99; S 13.72. 
(E,Z)-2-[6-Methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-Nʹ-[1-(4-nitrophenyl)ethylidene]acetohydrazide 
(compound 10) 
Yellow solid. Recrystallization from n-BuOH. Yield: 0.35 g (76%); m.p. 169-170°C. IR (KBr) in cm−1: 1630 
(nС=О), 3280 (nN-H), 1520 (dN-H); 1572-1591 (С=С, С=N), 2960 (nC-H), 1560 (nas), 1350 (ns) (NO), (1443 
(dC=C6-CH3), 1167, 1050 (C-O-C). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.39 (Z), 2.43 (E) (3Н, s,
 6C–CH3,), 3.26-
3.46(E), 3.51-3.71 (Z) (4H, m, S(CH2)2), 5.14-5.26 (E, Z) (1H, m, OCH), 6.11 (E), 6.26 (Z) (1H, s, 
5C–H), 3.93 (Z), 
4.05 (E) (1H, s, SCH2CO), 9.98 (E), 10.57 (Z) (1H, wid s, CONH), 2.39 (E), 2.43 (Z) s (3H, N=C(CH3)); 8.07 (E, Z) d 
(2Нarom, J 8,7 Hz), 8.34 (E, Z) d (2Нarom, J 8,6 Hz). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.11 (Z), 2.28 (E) (3Н, s,
 
6C–CH3,), 3.26-3.30(E), 3.41-3.52 (Z) (4H, m, S(CH2)2), 5.75-5.87 (E, Z) (1H, m, OCH), 6.17 (E), 6.31 (Z) (1H, s, 
5C–H), 3.92 (Z), 4.39 (E) (1H, s, SCH2CO), 9.30 (E), 9.91 (Z) (1H, wid s, CONH), 2.32 (E), 2.43 (Z) s (3H, 
N=C(CH3)); 6.91 (E, Z) d (2Нarom, J 8,7 Hz), 7.51 (E, Z) d (2Нarom, J 8,6 Hz). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 
163.78 (E, Z) (C6); 23.71 (E); 23.97 (Z) (6C-CH3); 102.22 (E); 103.37 (Z) (
5CH); 167.45 (E, Z); (4C); 69.43 (E); 
70.22 (Z) (OC3); 35.09 (Z); 35.49 (E) (SC2,4); 169.32 (E, Z) (2C); 40.89 (E); 41.20 (Z) (2-SCH2CO); 170.90 (E, Z) (2-
SCH2CO); 12,87 (E), 16,48 (Z) (=C(CH3)); 127,77 (E, Z) (4СНarom), 150,26 (E, Z) (Сarom); 143,60 (E, Z) (2Сarom). 
Found,%: C 49.87; H 4.42; N, 16.16; S 14.79. C18H19N5O4S2. Calculated,%: C 49.87; H 4.42; N, 16.16; S 14.79. 
(E,Z)-Nʹ-[1-(4-hydroxyphenyl)ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide 
(compound 11) 
White solid. Recrystallization from EtOH. Yield: 0.33 g (79%); m.p. 188-189 °C. IR (KBr) in cm−1: 3564 (O-
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H), 3109, 3073 (С-Нarom), 1667 («amide I»), 1591, 1569 (С=N, С=С), 1541 (δ NH, «amide II»), 1513 (N=C), 
1167 (nas), 1053 (ns) (C-O-C). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.39 (Z), 2.43 (E) (3Н, s,
 6C–CH3,), 3.26-3.47 
(E), 3.52-3.71 (Z) (4H, m, S(CH2)2), 5.14-5.26 (E, Z) (1H, m, OCH), 6.11 (E), 6.26 (Z) (1H, s, 
5C–H), 3.93 (Z), 4.05 
(E) (1H, s, SCH2CO), 9.98 (E), 10.57 (Z) (1H, wid s, CONH), 1.69 (E), 1.81 (Z) s (3H, N=C(CH3)); 9.68 (E, Z) wid s 
(OН), 7.74 (E, Z) d (2Нarom, J 8,7 Hz), 6.82 (E, Z) d (2Нarom, J 8,6 Hz). 
13C NMR (125,5 MHz, CDCl3, δ, ppm): 
163.78 (E, Z) (C6); 23.71 (E); 23.97 (Z) (6C-CH3); 102.22 (E); 103.37 (Z) (
5CH); 167.45 (E, Z); (4C); 69.43 (E); 
70.22 (Z) (OC3); 35.09 (Z); 35.49 (E) (SC2,4); 168.52 (E, Z) (2C); 33.30 (E); 33.78 (Z) (2-SCH2CO); 170.90 (E, Z) (2-
SCH2CO); 12,87 (E), 13,48 (Z) (=C(CH3)); 123,97 (E, Z) (2СНarom); 132,49 (Z), 133,64 (E) (2СНarom); 137,56 (E, Z) 
(2Сarom); 147,30 (E, Z) (=C(CH3)). Found,%: C 53.44; H 4.98; N 13.85; S 15.85. C18H20N4O3S2. Calculated,%: C 
53.45; H 4.98; N 13.85; S 15.85. 
(E,Z)-Nʹ-[1-(2,5-dihydroxyphenyl)ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)-pyrimidin-2-ylthio]-
acetohydrazide (compound 12) 
White solid. Recrystallization from i-PrOH. Yield: 0.36 g (81%); m.p. 180-181 °C.. IR (KBr) in cm−1: 3254 
(O-Н), 1667 («amide I»), 1591, 1572 (С=N, С=С), 1533 («amide II»), 1485 (N=C), 1167 (nas), 1044 (ns) (C-O-C). 
1H NMR (300 MHz, CDCl3, δ, ppm): 2.07 (Z), 2.15 (E) (3Н, s,
 6C–CH3,), 3.29-3.41 (E), 3.52-3.71 (Z) (4H, m, 
S(CH2)2), 5.14-5.26 (E, Z) (1H, m, OCH), 6.11 (E), 6.26 (Z) (1H, s, 
5C–H), 3.93 (Z), 4.05 (E) (1H, s, SCH2CO), 9.98 
(E), 10.57 (Z) (1H, wid s, CONH), 1.69 (E), 1.82 (Z) s (3H, N=C(CH3)); 13.18 (E, Z) wid s (OН), 9.46 wid s 
(OН),6.66 (E, Z) d (2Нarom, J 8,4 Hz), 6.75 (E, Z) d (2Нarom, J 8,6 Hz), 7.08 (E, Z) d (2Нarom, J 8,7 Hz). 
13C NMR 
(125,5 MHz, CDCl3, δ, ppm): 163.78 (E, Z) (C
6); 23.71 (E); 23.97 (Z) (6C-CH3); 102.22 (E); 103.37 (Z) (
5CH); 
167.45 (E, Z); (4C); 69.43 (E); 70.22 (Z) (OC3); 35.09 (Z); 35.49 (E) (SC2,4); 168.52 (E, Z) (2C); 33.30 (E); 33.78 (Z) 
(2-SCH2CO); 170.90 (E, Z) (2-SCH2CO); 12,87 (E), 13,48 (Z) (=C(CH3)); 116,37 (E, Z) (СНarom); 119.62 (E, Z) 
(СНarom); 120.42 (E, Z) (СНarom); 120.21 (E, Z) (Сarom); 151.21 (E, Z) (Сarom); 155.51 (E, Z) (Сarom); 147,30 (E, Z) 
(=C(CH3)). Found,%: C 51.41; H 4.79; N, 13.32; S 15.25. C18H20N4O4S2. Calculated,%: C 51.41; H 4.79; N, 
13.32; S 15.25. 
Biological studies 
Antibacterial and antifungal activities of the novel 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-
ylthio]acetohydrazide derivatives were analyzed using the agar diffusion and the tenfold broth (pH 7.2 – 
7.4) dilution methods. Microbial strains of the department of Microbiology and Virology, Bashkir State 
Medical University deposited at L.A. Tarasevich State Institute of Standardization and Control of Biomedical 
Preparations, the Ministry of Health of the Russian Federation were used as test organisms: E. coli, C. 
diversus, Ent. aerogenes, P. vulgaris, K. pneumoniae, Ps. aeruginosa, St. aureus, Str. pyogenes and lower 
fungi C. albicans. Test compounds (10 mg) were weighed and dissolved in 1 ml DMSO. These solutions were 
diluted in beef extract broth to achieve a final concentration of 0.1 mg/ml (stock solution). The nutrient 
broth, which contained logarithmic serially twofold diluted amount of test compound inoculated with  
2.0∙106 c.f.u/ml, was used. The cultures were incubated for 24 h at 37 °C and the growth was monitored 
visually. The lowest concentration (highest dilution) required to arrest the growth of bacteria was regarded 
as minimum inhibitory concentration (MIC). 
Results and Discussion 
Chemistry 
This study was undertaken to synthesise acetohydrazide derivatives. Synthesis of the desired compound 
2 was carried out as depicted in Figure 1. The structure of hydrazide 2 was confirmed by a complex of NMR 
spectroscopy methods. 
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E,Z-isomerism was observed in acetohydrazide 2, due to the inhibited rotation around the N-C hydrazide 
bond, as evidenced by the doubling of the proton signals of the thioacetohydrazide fragment. The spatial 
form of hydrazide 2 in DMSO-d6 was established using two-dimensional NMR spectroscopy methods: 
NOESY and ROESY (Figure 2). According to the spectral data, the sterically more stable Z-conformer 
prevails, as evidenced by the presence of the nuclear Overhauser effect between the signal of the 
methylene protons of the acetamide group, and the signal of the proton bonded to the nitrogen atom of 
the hydrazide fragment, indicating that these protons are closer in space. 
 




H ROESY spectrum (500 MHz, DMSO-d6) and structural schematic presentation 
of compound 2  
The signals of Z-conformer protons are registered in a stronger field in comparison with the same signals 
of the E-conformer. According to the 1H NMR spectra, the ratio of conformers is 19 (Z): 1(E). 
These hydrazones might exist in the form of E,Z-isomers due to hindered rotation around the N-CO bond 
and Eʹ,Zʹ-isomers around the C=N bond. The presence of two sets of chemical shifts in the 1H NMR spectra 
indicates that these compounds exist as a mixture of two stereoisomers. 
Acetone hydrazone might exist only as E',Z'-isomers; and two sets of chemical shifts in the 1H NMR 
spectra can be caused only by hindered rotation around the N-CO bond. 
Two sets of proton signals are recorded in the 1H NMR spectra of compound 3, dissolved in polar 
solvents. When a solution of compound 3 in DMSO-d6 is heated, coalescence occurs and the two sets of 
isomer signals merge into one. It confirms that the synthesized hydrazones in polar solvents exist as a 
mixture of two conformational E,Z isomers. Analysis of the 1Н NMR spectrum of hydrazone in DMSO-d6 at 
20.6° C showed that the signals of the protons of the СН2СО, NH groups - one of the methyl groups 
(СН3)2С=N of the E isomer - are shifted to a weaker field than the corresponding signals of the Z-isomer, 
which is consistent with the existing literature data. It is established that the sterically more stable EN-CO 
isomer predominates, according to the analysis of the integral intensities of the 1H NMR spectrum signals of 
hydrazone 3. 
In the 1H NMR spectrum of hydrazone 3, in non-polar solvents, i.e. benzene, one set of resonance signals 
was recorded, in which the values of the chemical shift indicate that hydrazone 3 in this case exists only in 
amide E-form. 
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Antimicrobial and antifungal activity 
Synthesized compounds were further screened for minimum inhibitory concentration against test 
organisms: E. coli, C. diversus, Ent. aerogenes, P. vulgaris, K. pneumoniae, Ps. aeruginosa, St. aureus, Str. 
pyogenes and lower fungi C. albicans. Minimum inhibitory concentration values are given in Table 1. 
Table 1. Antibacterial and antifungal activities of the newly prepared compounds 
Compound 



















1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
2 0.5 0.05 0.5 0.05 0.05 0.05 0.5 0.05 0.5 
3 50 5 0.5 5 0.05 0.05 0.05 0.05 0.05 
4 5 0.5 0.5 0.5 0.05 0.05 5 0.05 0.5 
5 50 5 0.05 5 5 0.5 0.05 5 0.5 
6 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.5 0.05 
7 0.5 0.5 0.5 0.5 0.05 0.05 0.5 0.05 0.05 
8 50 0.5 0.5 5 0.5 0.5 0.5 0.5 0.05 
9 50 5 5 5 0.5 5 5 0.5 5 
10 50 5 0.5 5 5 0.5 0.05 5 5 
11 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
12 0.05 0.05 0.5 0.05 0.05 0.05 0.05 0.05 0.05 
ceftriaxone 0.5 0.5 0.5 0.5 0.05 0.05 0.05 0.5 0.05 
Pimafucin - - - - - - - - 0.05 
The investigation of antibacterial screening data revealed that the compounds 6, 11 and 12 showed 
good inhibition towards all tested gram-positive and gram-negative bacteria, and lower fungi C. albicans. 
The derivative of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide 7, prepared in reaction 
with acetophenone, showed good antibacterial (MIC 0,05 – 0,5 µg/ml) and antifungal (MIC 0.05 µg/ml) 
activities, but it showed weak antimicrobial activity (MIC 0.5 µg/ml) against Pseudomonas aeruginosa. 
Compounds 8, 9 and 10 are less active against St. aureus, P. vulgaris. The results of antifungal testing 
revealed that compounds 1, 2, 4, 5, 9 and 10 are less active against C. albicans. All the other derivatives 
showed moderate activity against C. albicans. 
The structure–activity studies showed that, depending on the nature of the hydrazide fragment, the 
newly synthesized compounds exhibited varying degrees of microbial inhibition. It was found that 
hydrazide showed better activity, as compared to the ester against Str. pyogenes, P. vulgaris, K. pneumonia, 
Ent. aerogenes, E. cloacae. The presence of alkyl fragments such as methyl and ethyl radicals decrease 
activity against Str. pyogenes, P. vulgaris. The presence of a cyclohexylidene substituent increases 
antimicrobial activities E. coli, Ps. aeruginosa, reduces antimicrobial activities against St. aureus, Str. 
pyogenes, P. vulgaris, K. pneumonia, Ent. aerogenes, E. сloacae. Within the same series the antimicrobial 
activity depends on the nature of the substituent attached to the benzene ring. Based on the data obtained 
it was possible to investigate some structure-activity relationships: OH, NH2 groups in the benzene 
fragment in the molecule led to an increase in antimicrobial and antifungal activities; compounds with 
halogen, NO2 groups in the benzene ring are the least active. The OH group attached to a benzene ring 
increased the inhibitory activity of compounds against St. aureus. Str. pyogenes, P. vulgaris, Ps. aeruginosa. 
Thus, the nature of the substituent on the benzene ring attached to 2-[6-methyl-4-(thietan-3-
yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives has a strong influence on the extent of antimicrobial 
activity. 
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Conclusions 
New 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives have been success-
fully obtained and tested as potential antimicrobial and antifungal agents. N-ylidenehydrazides were 
synthesized by the reaction of hydrazide with alkyl and aryl ketones, without the use of acid catalysers, with 
good yields of 61–89%. We have characterized a hydrazone-based molecular switch and studied the 
isomerization mechanism of this acetohydrazide system. Solvent and temperature induced switching 
between E,Z-isomers. The synthesized compounds 1-12 have been investigated for their in vitro 
antibacterial and antifungal activities. It was found that the compounds Nʹ-[1-(4-Aminophenyl)ethylidene]-
2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide (compound 6), Nʹ-[1-(4-hydroxyphenyl)-
ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide (compound 11), Nʹ-[1-(2,5-
dihydroxyphenyl)ethylidene]-2-[6-methyl-4-(thietan-3-yloxy)-pyrimidin-2-ylthio]acetohydrazide (compound 
12) obtained from the reaction of p-aminoacetophenone, p-hydroxyacetophenone and 2,5-
dihydroxyacetophenone exhibit high antimicrobial and antifungal activity. Highest antifungal activity was 
observed in compounds 3, 6, 7, 8, 11 and 12. Compounds that contain thietan and pyrimidine in their 
molecules are suitable candidates for further chemical modifications and are pharmacological active. 
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